GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain barrier crossing technology after a trial period. If Novartis decides to buy the ...
Daiza Gordon watched her two younger brothers die when they were adolescents. They had Hunter syndrome, a rare, incurable disease — predominantly affecting boys — in which a gene for an important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback